Chaitman Martin, Dixit Deepali, Bridgeman Mary Barna
P T. 2016 Jan;41(1):43-50.
Use of sodium polystyrene sulfonate (SPS) dominates the long-term treatment of hyperkalemia, but two new agents, sodium zirconium cyclosilicate and the recently FDA-approved patiromer, may offer potential advantages compared with SPS.
聚苯乙烯磺酸钠（SPS）的使用在高钾血症的长期治疗中占主导地位，但两种新药，环硅酸锆钠和最近获得美国食品药品监督管理局（FDA）批准的帕替罗姆，与SPS相比可能具有潜在优势。
